Notably, dysfunction mutations of NF1 induce BRAF inhibitor resistance by activating RAS and its downstreams including both MAPK and PI3K/AKT/mTOR pathways in cutaneous melanoma [381, 382]. The gene discussed is MTOR; the disease is cutaneous melanoma.